Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lidocaine/prilocaine - Plethora Solutions

Drug Profile

Lidocaine/prilocaine - Plethora Solutions

Alternative Names: Fortacin; Prilocaine Lidocaine Plethora; Prilocaine/lidocaine; PSD-502; Tempe

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plethora Solutions
  • Class Acetanilides; Anilides; Class Ib antiarrhythmics; Erectile dysfunction therapies; Local anaesthetics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Premature ejaculation
  • Discontinued Pain

Most Recent Events

  • 20 Sep 2019 The Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion for Senstend (lidocaine/prilocaine), for the treatment of premature ejaculation in adult men, evaluated based on informed consent application .
  • 30 Jul 2019 Lidocaine/prilocaine is not yet available for Premature ejaculation in Iceland, Norway and Liechtenstein
  • 04 Feb 2019 Chemical structure information added
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top